

## Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended March 31, 2022

Revenue (\$ thousands)	2020				2021				2022	2020	2021
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	FY	FY
<b>Total U.S. NeuroStar Advanced Therapy System Revenues</b>	<b>\$2,594</b>	<b>\$2,338</b>	<b>\$2,541</b>	<b>\$3,620</b>	<b>\$1,755</b>	<b>\$2,577</b>	<b>\$2,612</b>	<b>\$2,815</b>	<b>\$3,642</b>	<b>\$11,094</b>	<b>\$9,760</b>
<i>YoY Change</i>	-23%	-49%	-45%	-33%	-32%	10%	3%	-22%	108%	-38%	-12%
<b>Total U.S. Treatment Sessions Revenues</b>	<b>\$8,193</b>	<b>\$6,547</b>	<b>\$9,083</b>	<b>\$11,029</b>	<b>\$9,629</b>	<b>\$10,801</b>	<b>\$10,259</b>	<b>\$11,245</b>	<b>\$9,469</b>	<b>\$34,852</b>	<b>\$41,933</b>
<i>YoY Change</i>	-7%	-40%	-11%	-2%	18%	65%	13%	2%	-2%	-15%	20%
<b>Total U.S. Other Revenues</b>	<b>\$390</b>	<b>\$382</b>	<b>\$404</b>	<b>\$397</b>	<b>\$419</b>	<b>\$431</b>	<b>\$409</b>	<b>\$496</b>	<b>\$406</b>	<b>\$1,574</b>	<b>\$1,754</b>
<i>YoY Change</i>	-7%	-8%	-5%	6%	7%	13%	1%	25%	-3%	-4%	12%
<b>Total U.S. Revenues</b>	<b>\$11,177</b>	<b>\$9,267</b>	<b>\$12,029</b>	<b>\$15,046</b>	<b>\$11,802</b>	<b>\$13,809</b>	<b>\$13,280</b>	<b>\$14,556</b>	<b>\$13,517</b>	<b>\$47,519</b>	<b>\$53,447</b>
<i>YoY Change</i>	-11%	-42%	-21%	-12%	6%	49%	10%	-3%	15%	-22%	12%
<b>Total International Revenues</b>	<b>\$299</b>	<b>\$474</b>	<b>\$419</b>	<b>\$533</b>	<b>\$486</b>	<b>\$394</b>	<b>\$519</b>	<b>\$466</b>	<b>\$664</b>	<b>\$1,725</b>	<b>\$1,865</b>
<i>YoY Change</i>	64%	-31%	-41%	64%	63%	-17%	24%	-13%	36%	-9%	8%
<b>Total Revenues</b>	<b>\$11,476</b>	<b>\$9,741</b>	<b>\$12,448</b>	<b>\$15,579</b>	<b>\$12,288</b>	<b>\$14,203</b>	<b>\$13,799</b>	<b>\$15,022</b>	<b>\$14,181</b>	<b>\$49,244</b>	<b>\$55,312</b>
<i>YoY Change</i>	-10%	-41%	-22%	-10%	7%	46%	11%	-4%	15%	-21%	12%
<b>U.S. Operating and Financial Metrics</b>	<b>2020</b>				<b>2021</b>				<b>2022</b>	<b>2020</b>	<b>2021</b>
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	FY	FY
<b>Total NeuroStar Systems Shipped (1)</b>	<b>38</b>	<b>35</b>	<b>39</b>	<b>54</b>	<b>23</b>	<b>36</b>	<b>40</b>	<b>48</b>	<b>48</b>	<b>166</b>	<b>147</b>
<i>YoY Change</i>	-12%	-43%	-43%	-31%	-39%	3%	3%	-11%	109%	-34%	-11%
<b>Average Revenue Per Active Site (\$) (2)</b>	<b>\$9,418</b>	<b>\$7,406</b>	<b>\$10,218</b>	<b>\$12,133</b>	<b>\$10,512</b>	<b>\$12,001</b>	<b>\$11,163</b>	<b>\$12,183</b>	<b>\$9,874</b>		
<i>YoY Change</i>	-24%	-50%	-22%	-10%	12%	62%	9%	0.4%	-6%		

(1) = All NeuroStar Systems shipped during the period, including Capital Sales, Sales-Type-Leases, Operating Leases for Q3 2021 (7), Q4 2021 (11), Q1 2022 (1), and units shipped and expected to be recognized in the period following Q1 2022 (2)

(2) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)